Imunon annual net debt
2012
2013
2017
2018
2019
2020
2021
2022
2023
2024
2025
Imunon Net Debt Growth & History (IMNN)
Imunon's net debt was −$7.8M for fiscal 2025.
View full Imunon company overviewImunon annual net debt history
| Fiscal year | Period ended | Net debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$7.8M | −$3.0M | — |
| 2024 | 2024-12-31 | −$4.7M | −$519,622 | — |
| 2023 | 2023-12-31 | −$4.2M | $1.1M | — |
| 2022 | 2022-12-31 | −$5.3M | $13.5M | — |
| 2021 | 2021-12-31 | −$18.8M | −$7.8M | — |
| 2020 | 2020-12-31 | −$11.0M | −$15.4M | — |
| 2019 | 2019-12-31 | $4.5M | $7.1M | — |
| 2018 | 2018-12-31 | −$2.6M | $8.7M | — |
| 2017 | 2017-12-31 | −$11.4M | — | — |
| 2013 | 2013-12-31 | −$707,613 | $9.3M | — |
| 2012 | 2012-12-31 | −$10.0M | — | — |
Imunon quarterly net debt
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q4.13
Q1.14
Q2.14
Q4.17
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
| Fiscal quarter | Period ended | Net debt | Change | YoY change |
|---|---|---|---|---|
| Q1 2026 | 2026-03-31 | −$3.9M | −$2.0M | — |
| Q4 2025 | 2025-12-31 | −$7.8M | −$3.0M | — |
| Q3 2025 | 2025-09-30 | −$4.1M | $4.9M | — |
| Q2 2025 | 2025-06-30 | −$3.5M | $382,066 | — |
| Q1 2025 | 2025-03-31 | −$1.9M | −$1.0M | — |
| Q4 2024 | 2024-12-31 | −$4.7M | −$519,622 | — |
| Q3 2024 | 2024-09-30 | −$9.0M | $2.1M | — |
| Q2 2024 | 2024-06-30 | −$3.9M | $1.3M | — |
| Q1 2024 | 2024-03-31 | −$838,305 | $2.0M | — |
| Q4 2023 | 2023-12-31 | −$4.2M | $1.1M | — |
| Q3 2023 | 2023-09-30 | −$11.1M | $9.4M | — |
| Q2 2023 | 2023-06-30 | −$5.3M | $15.0M | — |
| Q1 2023 | 2023-03-31 | −$2.8M | $19.0M | — |
| Q4 2022 | 2022-12-31 | −$5.3M | $13.5M | — |
| Q3 2022 | 2022-09-30 | −$20.6M | −$1.7M | — |
| Q2 2022 | 2022-06-30 | −$20.3M | −$542,958 | — |
| Q1 2022 | 2022-03-31 | −$21.8M | $9.8M | — |
| Q4 2021 | 2021-12-31 | −$18.8M | −$7.8M | — |
| Q3 2021 | 2021-09-30 | −$18.9M | −$6.8M | — |
| Q2 2021 | 2021-06-30 | −$19.7M | −$8.4M | — |
| Q1 2021 | 2021-03-31 | −$31.6M | −$37.2M | — |
| Q4 2020 | 2020-12-31 | −$11.0M | −$15.4M | — |
| Q3 2020 | 2020-09-30 | −$12.1M | −$14.9M | — |
| Q2 2020 | 2020-06-30 | −$11.3M | −$16.6M | — |
| Q1 2020 | 2020-03-31 | $5.6M | −$2.1M | −27.58% |
| Q4 2019 | 2019-12-31 | $4.5M | $7.1M | — |
| Q3 2019 | 2019-09-30 | $2.8M | −$3.1M | −52.83% |
| Q2 2019 | 2019-06-30 | $5.3M | $8.8M | — |
| Q1 2019 | 2019-03-31 | $7.7M | — | — |
| Q4 2018 | 2018-12-31 | −$2.6M | $8.7M | — |
| Q3 2018 | 2018-09-30 | $5.9M | — | — |
| Q2 2018 | 2018-06-30 | −$3.5M | — | — |
| Q4 2017 | 2017-12-31 | −$11.4M | — | — |
| Q2 2014 | 2014-06-30 | $402,592 | $1.7M | — |
| Q1 2014 | 2014-03-31 | $393,733 | $15.8M | — |
| Q4 2013 | 2013-12-31 | −$707,613 | $9.3M | — |
| Q2 2013 | 2013-06-30 | −$1.3M | $5.3M | — |
| Q1 2013 | 2013-03-31 | −$15.4M | — | — |
| Q4 2012 | 2012-12-31 | −$10.0M | — | — |
| Q3 2012 | 2012-09-30 | −$3.3M | — | — |
| Q2 2012 | 2012-06-30 | −$6.6M | — | — |
Imunon net debt trends
Over the last five fiscal years, Imunon's net debt increased from −$11.0M to −$7.8M, a change of $3.2M. The latest reported quarter, Q1 2026, shows −$3.9M.
About the metric
What net debt means
Net debt compares a company’s interest-bearing debt with its cash and cash equivalents. Positive net debt means debt exceeds cash, while a negative value indicates the company has more cash than debt on this measure.
Calculation and source
How net debt is calculated
TickerStat calculates net debt as total interest-bearing debt minus cash and cash equivalents at the same reporting-period end. Short-term investments are not subtracted because they are not included in the standardized cash series. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Imunon source filings ↗Community posts
IMUNON signs an NCI agreement to expand development of IMNN-001
IMUNON ($IMNN) entered a Cooperative Research and Development Agreement with the US National Cancer Institute for IMNN-001, its DNA-based IL-12 immunotherapy. NCI’s Cancer Therapy Evaluation Program will assume regulatory sponsorship and su ...